Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 16 of 16 publications.

Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho C, Reynolds M, Sherif B, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the GEOMETRY mono-1 study. Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030

Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi K. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur J Cancer. 2021 Jul 14;154:138-46.

Musetti S, Leaf H. Tinagl1 gene therapy for tumor-wide remodeling of triple negative breast cancer. Poster presented at the 2020 32nd EORTC-NCI-AACR Symposium; October 26, 2020. [abstract] Eur J Cancer. 2020 Oct 1; 138(2):S37-8. doi: 10.1016/S0959-8049(20)31172-2

Caballero-Banos M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pages M, Carrera G, Cuatrecasas M, Martin-Richard M, Cid J, Lozano M, Castells A, Garcia-Albeniz X, Maurel J, Vilella R. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients. Eur J Cancer. 2016 Sep;64:167-74. doi: 10.1016/j.ejca.2016.06.008

Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, Carroll PR, Hernan MA. Immediate vs. deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015 May;51(7):817-24. doi: 10.1016/j.ejca.2015.03.003

Graham CN, Hechmati G, Hjelmgren J, de Liege F, Lanier J, Knox H, Barber B. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2014 Nov;50(16):2791-801. doi: 10.1016/j.ejca.2014.08.016

Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X, Jares P, Castells A, Lozano JJ, Rosell R, Maurel J. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. Eur J Cancer. 2014 Jul;50(11):1973-81. doi: 10.1016/j.ejca.2014.04.019

Garcia-Albeniz X, Nan H, Valeri L, Morikawa T, Kuchiba A, Phipps AI, Hutter CM, Peters U, Newcomb PA, Fuchs CS, Giovannucci EL, Ogino S, Chan AT. Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival. Carcinogenesis. 2013 Feb;34(2):292-8. doi: 10.1093/carcin/bgs335

Sherrill B, Akhras K, Kaye J, Sandin R, Cappelleri J, Heyes A, Chen C. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology. Poster presented at the European Multidisciplinary Cancer Congress of the European Cancer Organization; September 24, 2011. Stockholm, Sweden. [abstract] Eur J Cancer. 2011 Sep 1; 47(Suppl. 1):S261.

Alguacil J, Kogevinas M, Silverman DT, Malats N, Real FX, Garcia-Closas M, Tardon A, Rivas M, Tora M, Garcia-Closas R, Serra C, Carrato A, Pfeiffer RM, Fortuny J, Samanic C, Rothman N. Urinary pH, cigarette smoking and bladder cancer risk. Carcinogenesis. 2011 Jun;32(6):843-7. doi: 10.1093/carcin/bgr048 PMID 21402590

Sharp L, Carsin AE, Cronin-Fenton DP, O'Driscoll D, Comber H. Is there under-treatment of pancreatic cancer? Evidence from a population-based study in Ireland. Eur J Cancer. 2009 May;45(8):1450-9. doi: 10.1016/j.ejca.2009.01.033

Cronin-Fenton DP, Sharp L, Carsin AE, Comber H. Patterns of care and effects on mortality for cancers of the oesophagus and gastric cardia: a population-based study. Eur J Cancer. 2007 Feb;43(3):565-75. doi: 10.1016/j.ejca.2006.10.011

Fortuny J, Benavente Y, Bosch R, García-Villanueva M, de Sevilla AF, de Sanjose S. Type 2 diabetes mellitus, its treatment and risk for lymphoma. Eur J Cancer. 2005 Aug;41(12):1782-7. doi: 10.1016/j.ejca.2005.04.032

Iida M, Anna CH, Hartis J, Bruno M, Wetmore B, Dubin JR, Sieber S, Bennett L, Cunningham ML, Paules RS, Tomer KB, Houle CD, Merrick AB, Sills RC, Devereux TR. Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643. Carcinogenesis. 2003 Apr 1;24(4):757-70.

Hershey N, Cann CI, Rothman KJ. Reply: overcoming hurdles to epidemiologic research. E & HR. 1985 Mar;7(2):9. doi: 10.2307/3564146

Cann CI, Rothman KJ. IRBs and epidemiologic research: how inappropriate restrictions hamper studies. E & HR. 1984 Jul;6(4):5-7. doi: 10.2307/3564590